By targeting functional proteins selectively produced within the Tumor Micro-Environment (TME),
we induce the tumor self-destruction.

To make this a therapeutic reality,
Seekyo has developed a disruptive TME Targeted Therapy for solid tumors :

Tumor Activated Therapy™

About Seekyo

Seekyo is a pre-clinical stage biotechnology company developing Tumor Micro-Environment targeted therapies.

Our vision is to provide solid cancer’s patients with safe and efficient treatments.
We aim at improving Patient’s quality of Life.

Seekyo is shifting to a new paradigm, the Tumor Activated Therapy™, revolutionizing the way solid tumors will be treated.

‍We have already validated efficacy and safety in both small and large animals.

Million deaths in the world
due to cancer

New cancer cases are diagnosed
each day worldwide

% of all cancers diagnosed
are solid tumors (lung,
breast, pancreas...)

% of all deaths are due to solid
tumors (lung, breast, pancreas...)

Therapeutic field

Cancer deaths usually result from the development of metastasis and the lack of curative approaches. At this latter stage of the disease, cancer chemotherapy remains often the only available therapeutic approach.
‍
However, most anticancer drugs lack intrinsic antitumor selectivity, resulting in serious side effects, one of the main causes of treatment failure.
‍
There is therefore an urgent need for better and innovative treatments for solid tumors.

Our Science

Tumor Activated Therapy™

Tumor growth induces many biochemical modifications of the micro-environment (TME) that are essential for cancer progression and dissemination.
‍
By taking advantage of the TME hallmarks, the Tumor Activated Therapy™ stimulates the tumor to induce its own destruction.

The Tumor Activated Therapy™ targets functional proteins produced by the tumor in the TME, enabling both tumor recognition and selective drug activation.
‍
Its Mode of Action is independent of any specific hallmarks of cancer cell (e.g. expression of specific surface markers like Antigens, membrane receptors…).
‍
This unique property allows to overcome issues associated to tumor heterogeneity.
‍
Additionally, a wide range of solid tumors (including difficult-to-treat tumors such as lung, pancreatic, Triple Negative Breast Cancer and colon cancers) can be successfully treated thanks to this novel and unique Mode of Action.

SKY01

We have developed our lead compound SKY01,
with a unique Mode of Action enabling :

A high plasmatic stability

A favorable Pharmacokinetics

A strong efficacy and evidence in several therapeutic indications including Difficult-to-treat cancers: Pancreas, TNBC, Lung, Collorectal...

A patient stratification with an in-house prognostic tool

A low Cost of Goods

Efficacy and safety are supported by data in small and large animals

Platform and pipeline

Based on Seekyo’s innovative molecular platform SKY™, we have successfully tested several combinations of active agents (cytotoxic drugs, immuno-stimulants….), targeting units and cleavable linkers adapted at targeting the TME.
‍
We are developing our internal programs SKY01 and SKY02 towards the Human Proof of concept.

Partnership

In addition to generating promising internal leads, Seekyo’s platform has the potential to optimize existing drugs (e.g. widening the therapeutic window…) for industrial partners.
‍
Bespoke optimization of marketed or in-development drugs is made available to customers.
‍
Furthermore we are developing our network of partners (big pharma, biotech, academics...) and constantly improving our innovative technology.

Partnership

Media

Contact